The company’s growth was driven largely by its integration of Remexian, which generated $31.6 million in revenue and saw its gross margins climb to 27%. This expansion in the German medical cannabis market, where High Tide now holds a 14% share, has provided a significant tailwind for the firm’s international ambitions. Founder and CEO Raj Grover noted that the company achieved these operational objectives roughly 90 days ahead of internal projections, citing improved supply chain efficiencies.

Domestically, the Canna Cabana retail chain continues to dominate the Canadian market, with membership in its Cabana Club loyalty program surpassing 2.65 million. The company successfully secured a $40 million senior secured credit facility from the Bank of Montreal to support further non-dilutive growth and expansion. Despite a challenging retail environment, High Tide maintained a 12% market share across its five active Canadian provinces, outpacing many industry competitors in key performance metrics. With a robust cash position and plans to add 20 to 30 new locations throughout the remainder of 2026, the company is positioning itself to capitalize on evolving regulatory landscapes in both North America and Europe.